Table 2.
Published case reports of renal transplantation in patients treated with autologous stem cell transplantation for multiple myeloma
| Reference | Patient demographics | Native kidney biopsy | MM treatment | Time to kidney transplant after remission (months) | Type of kidney transplant and immunosuppression | Last follow-up after kidney transplant (months) | Haematological response at last follow-up | eGFR at last follow-up (mL/min) |
|---|---|---|---|---|---|---|---|---|
| Lum et al. [10] | 67-year-old male | No biopsy but renal disease thought to be hypertensive nephrosclerosis. | Dexamethasone/bortezomib; bortezomib maintenance | 12 | Living unrelated transplant with basiliximab induction and maintenance with tacrolimus, mycophenolic acid and prednisolone and then ciclosporin and prednisolone (due to BK viraemia) | 25 | CR | 34 |
| 62-year-old female | Cast nephropathy | Plasmapheresis; dexamethasone/bortezomib; bortezomib maintenance | 24 | Living unrelated transplant with basiliximab induction and maintenance with tacrolimus and prednisolone | 13 | CR | 60 | |
| Hassoun et al. [13] | 42-year-old male | LCDD | Thalidomide/dexamethasone; dexamethasone; melphalan/dexamethasone/ doxorubicin/dexamethasone; cyclophosphamide mobilization; melphalan conditioning; ASCT | 14 | No details given | 22 | CR | Normal |
| 51-year-old female | LCDD | Thalidomide/dexamethasone; dexamethasone; melphalan/dexamethasone/ doxorubicin/dexamethasone; cyclophosphamide mobilization; melphalan conditioning; ASCT | 46 | No details given | 24 | CR | Normal | |
| Sánchez Quintana et al. [14] | 38-year-old male | LCDD | Dexamethasone; ASCT; lenalidomide maintenance | 48 | Deceased donor transplantation (DBD); no induction details given; maintenance with tacrolimus and prednisolone | 48 | CR | Not given |
| 44-year-old female | No biopsy | Vincristine/adriamycin/dexamethasone; ASCT; maintenance with thalidomide then lenalidomide | 48 | Deceased donor transplantation (DBD); no induction details given; maintenance with tacrolimus and prednisolone | 36 | VGPR | Not given | |
| Le et al. [15] | 52-year-old male | LCDD with cryoglobul-inaemic GN | Plasmapheresis, thalidomide/dexamethasone; vincristine/doxil/dexamethasone; cyclophosphamide mobilization; melphalan conditioning then ASCT | 66 | No details given | 58 | CR | 73 |
| 50-year-old male | No biopsy | Bortezomib/dexamethasone; lenalidomide/ doxorubicin/cyclophosphamide/dexamthasone; melphalan conditioning then ASCT lenalidamide followed by bortezomib maintenance; lenalidomide/dexamethasone (progression); carfilzomid/cyclophosphamide/dexamethasone; pomalidomide/cyclophosphamide/dexamethasone | 20 | ABO-incompatible kidney transplant with antithymocyte globulin induction | 48 | SD | 59 | |
| 50-year-old male | LCDD | Bortezomib/dexamethasone/lenalidomide; melphalan conditioning then ASCT; lenalidomide, then bortezomib maintenance | 32 | No transplant details given; no induction details given; maintenance with tacrolimus, mycophenolic acid and prednisolone | 43 | CR | 59 | |
| 47-year-old male | No biopsy | Bortezomib/dexamethasone/lenalidomide; cyclophosphamide mobilization; melphalan conditioning then ASCT; lenalidamide maintenance | 53 | No transplant details given with basiliximab induction and maintenance with tacrolimus and mycophenolic acid | 16 | CR | 60 |
SD, stable disease; LCDD, light chain deposition disease; DBD, donation after brain death; GN, glomerulonephropathy.